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Background: Countries in sub-Saharan Africa (SSA) are experiencing an epidemic of cardiovascular disease (CVD)
propelled by rapidly increasing rates of hypertension. Barriers to hypertension control in SSA include poor access to
care and high out-of-pocket costs. Although SSA bears 24% of the global disease burden, it has only 3% of the
global health workforce. Given such limited resources, cost-effective strategies, such as task shifting, are needed to
mitigate the rising CVD epidemic in SSA. Ghana, a country in SSA with an established community health worker
program integrated within a national health insurance scheme provides an ideal platform to evaluate implementation
of the World Health Organization (WHO) task-shifting strategy. This study will evaluate the comparative effectiveness of
the implementation of the WHO Package targeted at CV risk assessment versus provision of health insurance coverage,
on blood pressure (BP) reduction.
Methods: Using a cluster randomized design, 32 community health centers (CHCs) and district hospitals in Ghana
will be randomized to either the intervention group (16 CHCs) or the control group (16 CHCs). A total of 640
patients with uncomplicated hypertension (BP 140–179/90–99 mm Hg and absence of target organ damage) will
be enrolled in this study (20 patients per CHC). The intervention consists of WHO Package of CV risk assessment,
patient education, initiation and titration of antihypertensive medications, behavioral counseling on lifestyle
behaviors, and medication adherence every three months for 12 months. The primary outcome is the mean
change in systolic BP from baseline to 12 months. The secondary outcomes are rates of BP control at 12 months;
levels of physical activity, percent change in weight, and dietary intake of fruits and vegetables at 12 months; and
sustainability of intervention effects at 24 months. All outcomes will be assessed at baseline, six months and 12
months. Trained community health nurses will deliver the intervention as part of Ghana’s community-based health
planning and services (CHPS) program.
Discussion: Findings from this study will provide policy makers and other stakeholders needed information to
recommend scalable and cost-effective policy with respect to comprehensive CV risk reduction and hypertension
control in resource-poor settings.
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Ghana and other countries in sub-Saharan Africa (SSA)
are experiencing an epidemic of CVD propelled by rap-
idly increasing rates of hypertension [1]. According to
the World Health Organization (WHO), 75% of deaths
in SSA will be attributable to hypertension by the year
2020 [2]. Similar to most countries in SSA, Ghana is
undergoing a rapid epidemiological transition [3], such
that the last decade has seen major causes of death shift
from solely infectious diseases to a combination of com-
municable and non-communicable diseases (NCDs) [4].
Hypertension is the second leading cause of morbidity in
Ghana among adults older than 45 years [5]. In a sys-
tematic review of eleven surveys conducted in Ghana,
the prevalence of hypertension ranged between 19.3% in
rural areas to 54.6% in urban areas [6], and the levels of
hypertension detection, treatment, and control were
abysmally low in six studies where such data was re-
ported—blood pressure (BP) control rates were between
1.7% to 12.7%. Findings from a population-based study
by Cappuccio et al. showed that in the Ashanti Region
of Ghana, more than one in four adults have hyperten-
sion [7]. Such high prevalence and the abysmally low
rates of BP control is largely responsible for the increas-
ing burden of CVD mortality, particularly stroke, in
Ghana. For example, in Accra, CVD rose from being the
seventh and tenth cause of death in 1953 and 1966, to
the number one cause of death in 1991 and 2001, re-
spectively [8].
Thus, interventions targeted at BP control are vital to
reducing hypertension-related morbidity and mortality
[9,10]. However, socioeconomic barriers, lack of insur-
ance coverage, uncoordinated care, and shortage of phy-
sicians limit the capacity of SSA countries to implement
CVD prevention at the primary care level [9,11-15]. For
example, although SSA harbors 11% of the world’s popu-
lation and bears over 24% of global disease burden, it
has only 3% of the global health workforce, and spends
less than 1% of the world’s financial resources on health
[16]. Given such limited resources, cost-effective
systems-level strategies are urgently needed to mitigate
the rising epidemic of CVD in SSA [9,17]. To date how-
ever, little is known about effective interventions tar-
geted at BP control in SSA [18], especially notable is the
lack of interventions targeted at systems-level barriers to
optimal hypertension control on a wide-scale level in the
region.
Task shifting of healthcare duties from physicians to
non-physician healthcare providers (NPHCPs) at the pri-
mary care level may mitigate the barriers to optimal
hypertension control in SSA. Task shifting, which is de-
fined as the rational distribution of tasks among health
workforce teams, is especially useful in low-resource set-
tings facing healthcare human resource crisis [19], suchas SSA countries. Given the limited healthcare resources
and acute shortage of physicians in SSA, cost-effective
and affordable approaches are urgently needed to meet
the global challenge of the CVD epidemic in the region
[20]. In this context, shifting the tasks of CV risk assess-
ment and management of uncomplicated CV risk fac-
tors, such as hypertension and diabetes, from physicians
to non-physician healthcare providers such as nurses is a
viable and potentially cost-effective strategy. Task shift-
ing, has been proposed as a potential solution to not
only solving the acute shortage of physicians in SSA but
as a viable method to implement primary and secondary
prevention at the primary care level [21]. The benefits of
task shifting in addressing the HIV/AIDS epidemic in-
clude: increasing access to life-saving treatment; improv-
ing health-system efficiency; and enhancing the role of
the community [21]. Fortunately, primary and secondary
prevention of cardiovascular (CV) risk factors such as
hypertension, often involves lifestyle counselling, adop-
tion of self-management skills, and in some cases imple-
mentation of well-protocolized medication therapy that
can often be instituted by NPHCPs instead of the cost-
lier use of physicians [22]. There is growing evidence
that patients with hypertension can be cared for by
NPHCPs, who provide knowledge of the beneficial ef-
fects of a healthy lifestyle to patients almost as often as
physicians [20,22-24].
The conceptual framework for this study is based on
three viable, and potentially cost-effective strategies for
mitigating systems-level barriers to optimal hypertension
control in resource-poor settings: shifting integrated in-
terventions for CV risk reduction and hypertension con-
trol to primary care; task shifting of primary care duties
from physicians to non-physician healthcare providers
such as nurses for management of chronic diseases
[20,21,25]; and provision of health insurance coverage to
patients, who otherwise cannot afford the high out-of-
pocket payments and medications [26]. In this regard,
the World Health Organization (WHO) has developed a
Package of Essential Noncommunicable Disease Interven-
tion for Primary Care (WHO PEN) [25], which includes
clinical decision support for management of CVD via
easy-to-follow algorithms; lifestyle counseling; and drug
treatment protocols delivered by community health
nurses [25]. Its efficacy at improving BP control is well
proven in low- and middle-income countries (LMICs)
and is considered a ‘Best Buy’ [10,11,24]. However im-
plementation of this program is almost non-existent in
SSA. If these interventions do not find a place at the pri-
mary care level in SSA countries, their impact on public
health as well as the CVD epidemic would be negligible.
Two key aspects of the healthcare system in Ghana,
makes it a unique country to evaluate the implementa-
tion of WHO PEN. First, a key aspect of the healthcare
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Community-based Health Planning and Services (CHPS)
program as a strategy to use community health nurses
to deliver primary care services at community health
centers (CHCs) across the country [27]. The community
health nurse is the fulcrum of CHPS, and they play a
vital role in delivery of primary health care at both the
household and community level. The CHPS program
thus provides an opportunity for implementing task-
shifting strategy targeted at chronic diseases manage-
ment and may serve as a model for other LMICs. Sec-
ond, in 2003, Ghana instituted a National Health
Insurance Scheme (NHIS) that provides access to pri-
mary care, medical consultations, laboratory tests, and
medications at low cost [26]. Thus, availability of NHIS
for uninsured patients, and widespread implementation
of CHPS, as a strategy for delivery of primary care ser-
vices, presents a unique opportunity to evaluate the im-
pact of both strategies on hypertension control in
Ghana.
Study aims and hypothesis
This study will evaluate, among 640 hypertensive pa-
tients who receive care in CHCs in the Ashanti Region
of Ghana, the comparative effectiveness of the imple-
mentation of the WHO PEN program targeted at CV
risk assessment and hypertension control (intervention
group), versus provision of health insurance coverage
(control group), on BP reduction. The secondary aims
are to evaluate the effect of the WHO PEN program vs.
provision of health insurance coverage on BP control,
lifestyle behaviors, and the sustainability of the interven-
tion effects one year after the trial is completed. We
hypothesize that patients randomized to the intervention
group (IG) compared to those to control group (CG),
will have a greater reduction in systolic BP at 12 months,Receive Usual Care 
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Health Ins
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Figure 1 Overview of study design.a higher proportion of BP control at 12 months, higher
levels of physical activity; weight loss, and intake of fruits
and vegetables, and they will maintain higher BP control
rates and greater BP reduction at 24 months (one year
after completion of the trial).
Methods
Study design
As shown in Figure 1, using a cluster randomized trial
design, 32 CHCs in the Ashanti Region of Ghana will be
randomly assigned to either the intervention group (16
CHCs) or the control group (16 CHCs). A total of 640
patients with uncomplicated hypertension (systolic BP
140 – 179 mm Hg or diastolic BP 90 – 99 mm Hg and
absence of target organ damage) will be enrolled in this
study with about 20 patients per CHC. Study outcomes
will be assessed every three months for one year, and
sustainability of intervention effects will be evaluated at
24 months (one year after the trial is completed). Pa-
tients at the CHCs randomized to the control group will
receive health insurance coverage in addition to usual
care. Patients at the CHCs randomized to the interven-
tion group will also receive health insurance coverage
plus the WHO PEN package that will be delivered by
trained community health nurses as indicated in the
treatment protocol. The WHO PEN protocol consists of
four basic steps: inquiry about patient’s health history
(heart attack, angina, stroke, transient ischemic attack,
diabetes, and lifestyle behaviors); physical and laboratory
examination (including BP measurements, anthropomet-
rics, urine dip stick, fasting glucose, and plasma choles-
terol); estimation of patient’s CV risk based on the
WHO risk charts (low, medium, or high); and subse-
quent initiation of drug therapy and lifestyle counselling
during follow-up visits [25]. Depending on the patient’s
CV risk, the treatment decisions include either ans Receive National  
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with high CV risk and (BP ≥180/100); or lifestyle coun-
selling on diet, physical activity, and tobacco cessation;
prescription of an antihypertensive medication; and
follow-up with a provider. The intervention will occur
every three months for 12 months during scheduled
study visits.
Study setting and participants
Participating CHCs were selected from areas that are
geographically distant from one another with equal
urban/rural mix in the Ashanti Region, which has about
170 community health centers. Potentially eligible pa-
tients will be identified from the CHCs through phys-
ician referrals and the community health nurses. The
study was approved by the Institutional Review Board of
New York University School of Medicine and the Com-
mittee for Human Research, Publications and Ethics at
Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana.
Health center recruitment and randomization
Eligible CHCs must have at least one community health
nurse employed in the CHPS program; be a certified
NHIS provider; and have basic capability for blood tests
[28]. Eligible CHCs were identified with the help of the
Kumasi Metropolitan Director of Health for the Ghana
Health Services, who oversees all the health centers in
the region. A total of 32 CHCs will be randomized in co-
horts of eight CHCs each for a total of four cohorts.
When recruitment for each cohort is completed, the
CHCs are randomized to the intervention or control
group in a 1:1 ratio. The sequence of randomization is
generated by the study statistician, and kept in sealed
opaque envelopes away from the study sites in accord-
ance with CONSORT guidelines [29]. Once the sites
have been recruited, they are informed of their
randomization group by telephone. Because of the na-
ture of the intervention, it is impossible to blind the pa-
tients, community health nurses, and the study
coordinators to the group assignment. However, the sali-
ent dimension that the study coordinator could possibly
affect is the primary outcome of BP measurements. To
mitigate this bias, we will use an automated BP device,
which prevents the study coordinator from influencing
in any manner the BP readings.
Staff recruitment and training
Nurses selected for the study were active workers at the
various health centers. Training procedures was central-
ized in Ghana and occurred before the start of the pro-
ject and then every six months during patient
recruitment. All study staff received training on the
study protocol, including the WHO CVD riskassessment package, techniques for collecting anthropo-
metric data, BP measurements, questionnaire adminis-
tration, blood draw, urine collection, and processing
techniques, which were standardized between health fa-
cilities. Study nurses received additional training in be-
havioral counselling techniques using motivational
interviewing (MI). Project coordinators and nurses re-
ceived training in proper procedures for obtaining in-
formed consent from all study participants and study
data collection. The study nurses are responsible for
screening, and referring patients with complicated
hypertension to a specialist; assisting with data collection
as necessary, and conducting the MI counselling ses-
sions with patients. All field staff involved in data collec-
tion were trained and certified before data collection
began.
Participant recruitment
Potentially eligible patients are identified from the CHCs
through physician referrals and the community health
nurses. Each CHC will recruit 20 consecutive patients
who meet the following eligibility criteria: registered to
receive care at the CHC; adults age 40 years and older;
have BP 140 – 179/90 – 99 mm Hg, are not receiving
treatment for hypertension; and are able to provide in-
formed consent. Given low literacy levels, consent will
be provided both verbally and in written form. Patients
will be excluded if they have a diagnosis of diabetes, cor-
onary artery disease, transient ischemic attacks, stroke,
heart failure, angina; BP ≥ 180/100 mm Hg; positive
urine dipstick for protein; are pregnant; and unable to
comply with the follow-up requirements or provide in-
formed consent. Patients found on examination to have
a history of transient ischemic attacks (TIAs), stroke,
heart failure, diabetes, angina, claudication, and BP ≥
180/100 mm Hg will be referred to the district hospitals
for further management.
Description of the intervention
Provision of health insurance coverage to patients in both
arms of the study
Patients in both arms of the study will receive health in-
surance coverage for 12 months. In 2003, Ghana insti-
tuted a National Health Insurance Scheme (NHIS) that
provides access to primary care, medical consultations,
laboratory tests, and medications at low cost [29]. The
rationale for the provision of health insurance for all pa-
tients is to eliminate socioeconomic and systems-level
barriers to optimal hypertension control that is well doc-
umented in SSA [28].
Intervention Group (IG)
In addition to NHIS coverage, patients at the CHCs ran-
domized to the IG will receive the WHO PEN [25,30],
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of CVD via easy-to-follow algorithms; lifestyle counsel-
ling; and drug treatment protocols delivered by trained
community health nurses as part of the widespread
CHPS program in Ghana. Linking the services of the
community health nurses to CHPS allows us to assess
the scalability of the WHO strategy for CV risk assess-
ment and optimal hypertension control in Ghana. The
community health nurses will deliver the protocol for
the WHO Package every three months for one year in
five study visits [10]. Briefly, once patients’ eligibility is
confirmed, trained community health nurses at the
intervention sites will take the patients’ medical history.
Next, they will measure the patients’ weight, height,
waist circumference, and BP with an automated device.
The community health nurse then performs laboratory
tests using point-of-care testing to assess fasting blood
glucose, cholesterol levels, and urine dipstick for pro-
teinuria. The information obtained from the medical his-
tory, physical examination, and laboratory tests are then
used by the nurse to assess patients’ CV risk with the
aid of the well validated WHO risk charts that are con-
textualized for each region [30]. Once the patient’s CV
risk is determined (low, medium or high), those with
high CV risk will be referred to the district hospital for
further management. The community health nurse will
initiate the treatment protocol for patients who are
at low or medium risk according to their BP level
using any one of the four major antihypertensive
medications—bendrofluazide, a diuretic; amlodipine, a
calcium channel blocker (CCB); Lisinopril, an angiotensin-
converting enzyme (ACE) inhibitor; and bisoprolol, a
beta-blocker (BB). Those with stage one hypertension will
receive 2.5 mg of bendrofluazide or 5 mg Amlodipine.
Thus, those patients with stage two hypertension
(BP160 – 179/90 – 99 mm Hg) will receive combination
therapy with two antihypertensive medications at low dose
using either a diuretic plus ACE inhibitor; or a CCB plus
ACE inhibitor; or a diuretic plus a BB; or a CCB plus a BB
following JNC-7 guidelines [31]. In either case, medication
titration will be initiated at subsequent study visits
every three months, if BP control is not achieved
[10]. Medications will be provided to patients for free
and they will not be required to pay for their clinic
visits. In addition, all patients will receive information
on the expected side effects of their medications and
asked to return to the health center if they experience
unexplained side effects. Finally, once the medications
have been prescribed, patients will be counselled on
lifestyle behaviors targeted at addressing barriers to
medication adherence, physical activity, dietary intake of
fruits and vegetables, and weight loss using motivational
interviewing techniques. The community health nurses
will be trained in delivery of the WHO Package for CVrisk assessment and in lifestyle counselling similar to that
used in the WHO-sponsored trial by Mendis et al. [10].
Control group (CG)
In addition to NHIS coverage, patients at the CHCs ran-
domized to the CG will receive usual care as determined
by their providers. They will be given information mate-
rials on hypertension and patient education about the
causes of hypertension and its treatment. Similar to the
IG, these patients will also have a total of five study visits
for 12 months (one every three months), during each
visit their BP will be assessed and the levels of lifestyle
behaviors including physical activity, dietary intake of
fruits and vegetables, and their weight will also be
assessed. These patients will not receive the WHO Pack-
age but will be encouraged to follow up with their
healthcare providers for the treatment of their
hypertension.
Procedures for data collection and study measures
Physiological/laboratory measures
Blood pressure measurements Three BP readings will
be taken by trained study coordinators using an auto-
mated BP monitor [32] with the patient seated comfort-
ably for five minutes prior to the measurements,
following the American Heart Association guidelines
[33]. The same procedure will be followed at six- and
12-month study visits. The average of the three BP read-
ings will be used as the measure for each visit. Uncon-
trolled BP is defined as average clinic SBP ≥140 mm Hg
or DBP ≥90 mmHg following JNC-7 guidelines [31].
Height and weight will be measured without shoes
using a tape rule and a validated digital scale respect-
ively. All measurements will be recorded to the nearest
0.1 cm and 0.1 kg respectively. These data will be used
to assess patients’ body mass index (BMI), which will
serve as a measure of weight loss.
Fasting blood specimen will be collected after an over-
night fast. The purpose of blood collection is to allow us
to evaluate indicators of CV risk (lipid profile, and fast-
ing glucose). This will be achieved by point of care test-
ing. The results of these data will be used to assess
patients’ CV risk score.
Self-report measures
The study data collection tools will be administered in
English because most participants speak and understand
English. However, trained study coordinators fluent in
Twi, will translate the data collection instruments to
illiterate participants on as needed basis. Twi is the dia-
lect spoken in Kumasi, the Ashanti Region where this
study is being undertaken.
Table 1 Sample size





*Total sample is the product of clinics and patients/clinic.
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Socio-demographic data will be used to describe the co-
hort and examine effects of these factors on the study
outcomes. Variables include age, gender, household in-
come, education level, marital status, and employment
status.
Medication adherence
Adherence to prescribed antihypertensive medications
will be assessed using the widely used and validated
four-item scale developed by Morisky that specifically
addresses adherence to prescribed medication regimen
[34]. Data on medication adherence will allow us to as-
sess the potential effect of adherence on BP control.
Dietary intake
Dietary intake will be assessed using a 24-hour food re-
call, a validated, self-administered instrument designed
to measure energy intake (kcal) and macronutrient in-
take during the previous 24 hours [35]. We will use a
validated system for portion size estimation which has
been utilized in multiple countries in SSA [36].
Physical activity
Physical activity will be assessed with the Global Physical
Activity Questionnaire, developed by the WHO for
physical activity surveillance in LMIC countries [37].
Chart extraction
Information extracted from the medical records will in-
clude medications and their dosages, BP measurements
from clinic visits, and medical comorbidity.
Outcome measures
The primary outcome is the mean change in systolic BP
from baseline to 12 months. The secondary outcomes
include proportion of patients with adequate BP control
at 12 months; levels of physical activity, percent change
in weight, and dietary intake of fruits and vegetables at
12 months; and BP control rates at 24 months. BP con-
trol is defined as BP < 140/90 mmHg following JNC-7
guidelines [31]. BP readings will be assessed with vali-
dated automated BP device. All study outcomes will be
assessed at baseline, six months, and 12 months.
Sample size and power analysis
The study is a two-arm cluster randomized trial with the
health center as the unit of randomization. Thus, there
are two important sample size estimates, N the number
of patients and K, the number of clinics, with the pa-
tients nested within the K clinics. The sample size calcu-
lations is based on a two-tailed alpha level of p = 0.05,
and power at 0.80. The effect size is based on a greater
reduction in SBP of 5 mm Hg in the IG compared to theCG. A standard deviation of SBP of 15 mm Hg [10],
which yields a standardized effect size of BP change
of d = 0.33 and an ICC of 0.06 consistent with the data
from the WHO-sponsored Mendis et. al trial in Nigeria
[10] was used to estimate the sample size. Based on this
information the combinations of clinics and patients/clinic
in Table 1 satisfies our desire for power = 0.80. Table 1
illustrates the flexibility in sample size estimates with
respect to both recruitment and attrition. For example, if
the recruitment goal is an average of 30 patients in each
clinic, but only an average of 20 per site was achieved, it
means six more clinics (26 + 6 = 32) will need to be
randomized to maintain a statistical power of 0.80.
Likewise, if an attrition rate of 25% among the 20 patients
was experiences, then four more clinics (32 + 4 = 36) will
need to be recruited in order to maintain the same power
level with an average of 15 completers/clinic.
Statistical methods
Analysis for primary hypotheses
We hypothesize that patients in the intervention group
will have greater systolic BP reduction than those in the
control group at 12 months. This analysis will be accom-
plished with a multilevel MANOVA (unstructured co-
variance matrix across three time points baseline, six,
and 12 months). This analysis will have one within-
person factor—time (baseline, six-month, and 12-month
follow-up) and one primary between-patient factor
(randomization group). The outcome measures in this
analysis will be systolic BP. Additionally the patients will
be nested within clinics creating a three-level analytic
model (observations nested within patients nested within
clinics). Multilevel modeling software (SAS, Version 9,
PROC MIXED) will be used to compute full-information
maximum likelihood (FIML) estimates of the model pa-
rameters [38]. The PROC MIXED procedure will use an
error structure that allows for the possibility of group
differences in the error variances at follow-up; and the
serial correlations of baseline BP with six- and 12-month
BP. The primary test concerns the Group X Time inter-
action, and the resulting F-test will provide the primary
‘intent-to-treat’ test of the hypothesis. If this is statisti-
cally significant at the two-tailed α = 0.05 level, for ease
of interpretation, we will estimate and report the magni-
tude of the treatment effect, with 95% CI for SBP.
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arm and the absence of significant selection and/or attri-
tion biases will obviate the need for any covariates in the
analysis. However, in the event that the above-described
probit analyses indicate one or more sources of potential
bias, the predicted values of those analyses will be in-
cluded as covariates in the MANOVA (including their
interactions with the within-person factors).
Analysis for secondary hypotheses
Secondary hypothesis one: patients in the intervention
group will have higher BP control rate than those in the
control group at 12 months
This hypothesis will be assessed with a 2 (group) × 2
(control) chi-square analyses as there is no time factor
in these analyses. However, we will use multilevel logistic
regression to control for the nesting of patients within
clinics. BP control will be defined as occurring when sys-
tolic BP < 140 mm Hg and diastolic BP < 90 mm Hg at
12 months. Effect sizes will be reported as odds ratios
with 95% CI. The covariates describe above will be in-
cluded in the analyses as needed. For those participants
without BP data at 12 months, we will estimate their BP
control using data from previous time points.
Secondary hypothesis two: patients in the intervention
group will have higher levels of physical activity, greater
weight loss, and intake of fruits and vegetables than those
in the control group at 12 months
Similar to the primary hypothesis testing, we will per-
form separate multilevel MANOVAs (observations
within person within health center) with one within-
patient factor (Time) and one between-patient factor
(Group) for the summary measure of physical activity,
weight, and the summary measure of intake of fruits and
vegetables. For each analysis, we will allow for group dif-
ferences in the variance of the outcome at follow-up and
the serial correlation of baseline with follow-up assess-
ments. Because changes in weight tend to be propor-
tional to baseline weight, we will follow the widely used
strategy of analysing the percent change in weight; thus,
there will be no within-patient component to this ana-
lysis per se, but we will allow for group differences in
the SD of percent change. Similar to the analysis for the
primary hypothesis, if evidence of selection or attrition
biases or group differences resulting from randomization
is detected, predicted values of the corresponding probit
analysis will be incorporated as covariates into these
analyses. However, we may consider introducing an ad-
justment to protect against the experiment-wide risk of
a Type I error. If so, we would use Holm’s modified
Bonferroni procedure, which is less conservative than
the traditional Bonferroni procedure, but still controls
for the experiment-wide α-level [39].Secondary hypothesis three: patients in the intervention
group will maintain higher BP control rates and greater
reduction of both SBP and DBP than those in the control
group at 24 months
These analyses will be identical to those for the primary
hypothesis except that an additional 24-month time
point will be added to the multilevel model. We will
consider a spline regression model to assess the possibil-
ity that there will be no further linear decrease in BP in
the groups, but simply a maintenance of the changes
achieved at 12 months.
Trial status
The study began in November 2012 and to date, we have
recruited and randomized all 32 community health cen-
ters. Patient recruitment is ongoing with about 60% of
the patients recruited to date. Follow up is almost com-
pleted for the first cohort of eight sites with a total of
190 patients; and the final cohort of eight sites was ran-
domized in January 2014.
Discussion
Although the prevalence of hypertension and its related
complications are well documented in SSA [40], few in-
vestigators have evaluated the effectiveness of interven-
tions targeted at BP control and CV risk in the region.
Fortunately, the WHO has undertaken extremely vital
programs and provided a roadmap, and an agenda to
tackle the hypertension crisis in LMIC, including SSA
[15]. One such program with respect to CV risk-
reduction is the strategy of task-shifting designed to ad-
dress the multiple layers of the CVD epidemic including
screening, counselling on lifestyle modification, initiation
of treatment, and referral to specialist care with the use
of community health workers [25]. Although the reliabil-
ity of having community health nurses deliver the WHO
strategy for CV risk assessment and optimal hyperten-
sion control when compared to ‘expert’ physicians in
primary care settings has been established in several
LMIC countries [41], its implementation is almost non-
existent in SSA. More importantly, in order for task-
shifting strategies to be considered effective, evidence of
its implementation for addressing the CVD epidemic as
part of existing healthcare systems in LMICs are para-
mount. Such studies integrated into existing healthcare
systems will guarantee subsequent adoption of interven-
tions if proven successful.
This study protocol addresses the gap in the literature
by evaluating implementation of the WHO Package in
community health centers in Ghana as part of the Ghana
Health Service—the major healthcare organization in the
country. Findings from this study, if successful, will
be important for several reasons. First, majority of the
population in SSA receive their care in community
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secondary and tertiary care centers due to very high
out-of-pocket payments and medication costs [42].
Second, the effectiveness of the WHO Package in primary
healthcare centers in LMICs has been successfully evalu-
ated making it ripe for implementation and potential
dissemination [10,41]. Third, a recent survey of primary
healthcare centers with respect to management of hyper-
tension, suggests that significant proportion of community
health workers initiated thiazide diuretics as first-line
therapy for hypertensive patients despite low knowledge
of hypertension treatment guidelines, thus supporting the
need to enhance this skill and its implementation at the
primary care level [28]. In the same survey, about two-
thirds of hypertensive patients utilized primary healthcare
centers both for diagnosis and for follow-up care. This
implies that primary healthcare centers have the potential
to contribute significantly to management of CVD, and
that targeting hypertension control at the primary care
level should yield better CV outcomes than population-
based approaches. Finally, this clinical trial addresses
important systems-level barriers to optimal hypertension
control in SSA. Although barriers to optimal hypertension
control exists at the level of the patients, providers, and
the healthcare systems [22], in SSA countries, systems-
level barriers seem to have more adverse impact on
healthcare in general, particularly among those with
chronic diseases [28]. In this regard, lack of access to care
(particularly among the poor), suboptimal staffing of
healthcare facilities, and limited capacity for laboratory
investigations that complement CV risk assessment are
major barriers limiting the capacity of countries in SSA to
manage CVD at the primary care level [9]. This situation
is made worse by the brain drain that has plagued SSA for
over 20 years [12,14]; with a resultant acute shortage
of health workers available to implement primary and
secondary CVD prevention at the primary care level.
Task shifting can be effective in mitigating this burden,
particularly among hypertensive patients.
If findings from the proposed study are successful, this
will provide the evidence-base for policy makers to rec-
ommend similar strategies across healthcare systems
with respect to comprehensive CV risk reduction and
hypertension control in resource-poor settings because
several SSA countries like Tanzania, Kenya, Cameroon,
and Nigeria have already implemented a healthcare sys-
tem that has at its hub the use of community health
workers to deliver primary care, making generalizability
of the proposed task-shifting strategy very feasible [42].
In Nigeria, for example, non-physician healthcare pro-
viders including public health nurses, nurse/midwives,
and community health workers are responsible for man-
aging primary healthcare facilities, which function as
outpatient clinics, while physicians manage secondaryand tertiary healthcare facilities. Non-physician health-
care providers are typically trained in nursing/midwifery
or community health extension work for a period ran-
ging from two to four years [43]. Similarly, national
health insurance scheme has been instituted in Nigeria
and assessment of its effectiveness in improving BP con-
trol in the uninsured patient would also provide the im-
petus for other SSA countries to adopt this strategy, if
proven successful.Conclusions
Ghana and other countries in SSA are experiencing an
epidemic of CVD propelled by rapidly increasing rates
of hypertension. Socioeconomic barriers, lack of insur-
ance coverage, and shortage of physicians limit the cap-
acity of SSA countries to implement CVD prevention.
Task shifting of primary care duties from physicians to
non-physician health care providers is a potentially cost-
effective strategy for mitigating systems-level barriers to
optimal hypertension control in SSA. In this regard, the
WHO developed and successfully evaluated the effect-
iveness of a WHO Package targeted at CV risk assess-
ment and hypertension control, delivered by community
health nurses (CHNs) in low resource settings. However
widespread implementation of the WHO Package has
not been evaluated in SSA. The availability in Ghana of
national health insurance scheme for uninsured patients,
and widespread implementation of CHPS program that
uses CHNs for delivery of primary care services, presents
a unique opportunity to evaluate the impact of both
strategies on hypertension control. Thus, this study will
evaluate the comparative effectiveness of the WHO
CVD risk management package for hypertension control
delivered by CHNs as part of Ghana’s CHPS program
plus provision of health insurance coverage, versus
provision of health insurance coverage alone, on BP re-
duction among 640 patients who receive care in 32
CHCs in Ghana. Findings from this study will provide
policy makers and other stakeholders needed informa-
tion to recommend scalable and cost-effective policy
with respect to comprehensive CV risk reduction and
hypertension control in resource-poor settings.Abbreviations
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